IDEXX Laboratories's Total Assets for the quarter that ended in Mar. 2026 was €2,928 Mil.
During the past 12 months, IDEXX Laboratories's average Total Assets Growth Rate was 4.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 6.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 10.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 12.50% per year.
During the past 13 years, IDEXX Laboratories's highest 3-Year average Total Assets Growth Rate was 49.60%. The lowest was -1.20%. And the median was 9.10%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
IDEXX Laboratories's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
IDEXX Laboratories Total Assets Related Terms
IDEXX Laboratories Total Assets Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
IDEXX Laboratories's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (FRA:IX1) has a Total Assets of €2,928 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Total Assets too high?
IDEXX Laboratories' current Total Assets is €2,928 Mil. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Total Assets compare to A and NTRA?
IDEXX Laboratories' Total Assets of €2,928 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Diagnostics & Research company?
A good Total Assets depends on the Medical Diagnostics & Research industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Total Assets is €2,928 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €562.69, compared to a current price of €469.00 — trading 16.7% below its estimated fair value. The current Total Assets is €2,928 Mil. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Total Assets is €2,928 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €469.00 is trading 16.7% below its estimated GF Value™ of €562.69.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
Total Assets: €2,928 Mil
GF Value™: €562.69 vs. price of €469.00 (16.7% below fair value)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
